Hyderabad: Cohance Lifesciences Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed an inspection of the company's manufacturing facility at Pashamylaram, Hyderabad. The company stated that it remains committed to maintaining the highest standards of quality and regulatory compliance. As part of its response, Cohance Lifesciences said it will implement appropriate Corrective and Preventive Actions (CAPAs) to address each of the observations raised by the USFDA. According to Cohance Lifesciences, the company remains dedicated to continuous improvement across its operations while sustaining robust quality systems that support patient safety and regulatory compliance. Also Read: Cohance Lifesciences announces USD 10 mn investment in cGMP Bioconjugation Suite at NJ Bio